Kyverna Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
14.1%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$2.88next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly236.4MTarget: Sufficient to fund operations into 2028
Quarterly Net Loss Quarterly-39.7MTarget: Stabilization post-commercialization
Quarterly Research and Development (R&D) Expenses Quarterly30.1MTarget: Optimized clinical trial spending
Watch Items
- Rolling BLA Submission for miv-cel in Stiff-Person Syndrome (SPS)Trigger: Completion of rolling submissionAction: Monitor FDA feedback and potential priority review timeline under RMAT designation
- Phase 3 KYSA-6 Trial Enrollment in Generalized Myasthenia Gravis (gMG)Trigger: Enrollment milestones and interim data updates in 2H 2026Action: Evaluate clinical site activation and patient recruitment speed
- Competitive Landscape in Autoimmune CAR-T SpaceTrigger: Clinical readouts from competitors (e.g., Bristol Myers Squibb's zola-cel, Cabaletta Bio)Action: Assess comparative efficacy, safety profiles, and manufacturing timelines
Research as of 19 Jun 2026